Source-grounded facts extracted from 4D Molecular Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
4D Molecular Therapeutics, Inc. reported the three months ended March 31, 2026 results: revenue $3.0 million, net income Net loss was $68.8 million.
“fund our operating expenses and capital expenditure requirements at least into the second half of 2028. Collaboration and License Revenue : Collaboration and license revenue was $3.0 million for the first quarter of 2026, as compared to an insignificant amount for the first quarter of 2025. The increase in revenue was primarily due to the clinical trial cost sharing”
Governance Changes
4D Molecular Therapeutics, Inc.: Board amended and restated Bylaws to update advance notice procedures for business brought before a meeting and for nominations of directors (effective 2025-09-30).
“On September 30, 2025, the Board amended and restated the Company’s current amended and restated bylaws (the “Amended and Restated Bylaws”). The Amended and Restated Bylaws were amended to, among other revisions, update the advance notice procedures for business brought before a meeting and update the advance notice procedures for nominations of directors.”
Earnings Releases
4D Molecular Therapeutics, Inc. reported financial results for the three months ended March 31, 2024.
“4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the three months ended March 31, 2024.”
Earnings Releases
4D Molecular Therapeutics, Inc. reported financial results for the year ended December 31, 2023.
“On February 29, 2024, 4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.